Literature DB >> 22520983

The antifolates.

Michele Visentin1, Rongbao Zhao, I David Goldman.   

Abstract

This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22520983      PMCID： PMC3777421          DOI： 10.1016/j.hoc.2012.02.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  103 in total

Review 1.  Resistance to antifolates.

Authors:  Rongbao Zhao; I David Goldman
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 2.  The folate receptor: what does it promise in tissue-targeted therapeutics?

Authors:  Marcela D'Alincourt Salazar; Manohar Ratnam
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

3.  Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors.

Authors:  John L Andreassi; Richard G Moran
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

Review 4.  The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

Authors:  Yehuda G Assaraf
Journal:  Drug Resist Updat       Date:  2006-11-07       Impact factor: 18.500

5.  A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.

Authors:  Rongbao Zhao; Feng Gao; Marie Hanscom; I David Goldman
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

Review 6.  Advances in the pathogenesis and treatment of IBD.

Authors:  Nicholas A Braus; David E Elliott
Journal:  Clin Immunol       Date:  2009-03-24       Impact factor: 3.969

7.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

Authors:  A L Jackman; G A Taylor; W Gibson; R Kimbell; M Brown; A H Calvert; I R Judson; L R Hughes
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

8.  A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.

Authors:  E C Taylor; D Kuhnt; C Shih; S M Rinzel; G B Grindey; J Barredo; M Jannatipour; R G Moran
Journal:  J Med Chem       Date:  1992-11-13       Impact factor: 7.446

Review 9.  Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism.

Authors:  B Shane
Journal:  Vitam Horm       Date:  1989       Impact factor: 3.421

10.  Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro.

Authors:  I Fabre; G Fabre; I D Goldman
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701
View more
  86 in total

1.  The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.

Authors:  Michele Visentin; Ersin Selcuk Unal; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-29       Impact factor: 3.333

2.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

3.  Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis.

Authors:  Elena Kamynina; Erica R Lachenauer; Aislyn C DiRisio; Rebecca P Liebenthal; Martha S Field; Patrick J Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

4.  Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.

Authors:  Mohammad A Rattu; Neal Shah; Jessica M Lee; Antony Q Pham; Nino Marzella
Journal:  P T       Date:  2013-12

5.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

6.  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Mike R Wilson; Nian Tong; Carrie O'Connor; Mohammad Karim; Lisa Polin; Adrianne Wallace-Povirk; Kathryn White; Juiwanna Kushner; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-04-27       Impact factor: 7.446

7.  Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.

Authors:  Yiqiang Wang; Christina Cherian; Steven Orr; Shermaine Mitchell-Ryan; Zhanjun Hou; Sudhir Raghavan; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

8.  Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Adrianne Wallace-Povirk; Mohammad A Karim; Mike R Wilson; Carrie O'Connor; Kathryn White; Juiwanna Kushner; Lisa Polin; Christina George; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-02-21       Impact factor: 7.446

9.  Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores).

Authors:  Khushbu Shah; Sudhir Raghavan; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Mol Graph Model       Date:  2018-02-20       Impact factor: 2.518

10.  Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Lalit K Golani; Adrianne Wallace-Povirk; Siobhan M Deis; Jennifer Wong; Jiyuan Ke; Xin Gu; Sudhir Raghavan; Mike R Wilson; Xinxin Li; Lisa Polin; Parker W de Waal; Kathryn White; Juiwanna Kushner; Carrie O'Connor; Zhanjun Hou; H Eric Xu; Karsten Melcher; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2016-08-26       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.